Coreshell and Elixir are the two customers where Anchor's publications face the highest risk of converting milestone into market conclusion. Both companies are in stretches where the decisive evidence generates no public signal.

Coreshell's public narrative shifted from commercial-format cells and planned A-sample delivery (December 2024) through strategic funding (March 2025) to domestic supply-chain sovereignty storytelling by 2026. "China Controls the Battery Supply Chain. Here's How America Breaks Free" is a real story. It also doesn't require Coreshell to have confirmed automaker acceptance of its samples. No reviewed source names an automaker that accepted A-samples (pre-production cells sent for qualification testing) or disclosed qualification results.

Elixir's version is structural rather than rhetorical: favorable company-presented trial data and CE Mark availability outside the U.S., while its own homepage still marks DynamX as investigational in the U.S. CE Mark does not predict FDA PMA (premarket approval) timing.

Both companies fill the vacuum left by invisible milestones with adjacent narratives. Sovereignty. European follow-up data. These narratives are legitimate, but they aren't the evidence that determines commercial outcome. A publication that tracks narrative momentum without policing the gap between milestone and market becomes marketing with better sourcing. The Hysteresis should be mapping what's absent from Coreshell's public record. Clear Path should be measuring the distance between clinical evidence and U.S. market access. Both publications should be making the dark stretch visible to the reader, not routing around it.

TinyFish and Okta both operate in domains where the vocabulary is still wet. Both are doing something structurally identical: claiming the standard before practitioners have ratified it. TinyFish calls WebVoyager "the standard independent benchmark" for browser agents. Okta calls Cross App Access "the new standard" for enterprise agent connections. In both cases the company honestly discloses boundary conditions in the body of the post. In both cases the framing does the opposite work, treating a narrow, early-stage result as settled consensus.

Note the asymmetry in what gets excluded. TinyFish's 91.1% accuracy covers 15 websites and explicitly leaves out latency, cost, and out-of-benchmark behavior. Okta shipped four major agent-auth integrations in six weeks while most XAA implementations remain beta or in-progress on OAuth.net's own tracker. The caveats exist; they just don't make it into the headline that circulates.

Anchor's cadence problem is sharpest here. Both domains move at a pace where a three-week-old claim has already been laundered through repetition into received wisdom. If the publications reproduce the headline, they're commodity. If they surface the boundary conditions the headline dropped, they're the only place a reader gets the full picture. A publication that echoes "91.1% accuracy" or "new standard" without the scope conditions is doing work the press release already did. Claim rigor is the entire value proposition in domains this fast.